Literature DB >> 17094597

[Molecular identification of naturally acquired Plasmodium knowlesi infection in a human case].

Hui Zheng1, Huai-min Zhu, Bei-fang Ning, Xiang-yu Li.   

Abstract

OBJECTIVE: To confirm the diagnosis of a human case with atypical vivax-malaria from Yunnan Province by molecular technique.
METHODS: DNA was extracted from blood films of unidentified sample, and of four known Plasmodium species (P. vivax, P. falciparum, P. knowlesi, and P. cynomolgi). A DNA-based diagnosis with the polymerase chain reaction (PCR) method targeting the small subunit ribosomal RNA (SSU rRNA) genes of genus- and species-specific (two human malaria species and P. knowlesi) was introduced.
RESULTS: The PCR amplification with primer pair specific for P. knowlesi produced a single fragment of 150 bp. Sequence analysis showed that the amplified fragment was identical to the sequence of P. knowlesi.
CONCLUSION: The patient was naturally infected with P. knowlesi.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094597

Source DB:  PubMed          Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi        ISSN: 1000-7423


  3 in total

Review 1.  Diagnosis of malaria: challenges for clinicians in endemic and non-endemic regions.

Authors:  Rachel N Bronzan; Meredith L McMorrow; S Patrick Kachur
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

2.  First case of detection of Plasmodium knowlesi in Spain by Real Time PCR in a traveller from Southeast Asia.

Authors:  Tang Thuy-Huong Ta; Ana Salas; Marwa Ali-Tammam; María Del Carmen Martínez; Marta Lanza; Eduardo Arroyo; Jose Miguel Rubio
Journal:  Malar J       Date:  2010-07-27       Impact factor: 2.979

3.  Quantification of the misidentification of Plasmodium knowlesi as Plasmodium malariae by microscopy: an analysis of 1569 P. knowlesi cases.

Authors:  Aongart Mahittikorn; Frederick Ramirez Masangkay; Kwuntida Uthaisar Kotepui; Giovanni De Jesus Milanez; Manas Kotepui
Journal:  Malar J       Date:  2021-04-09       Impact factor: 2.979

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.